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Background: This study aims to assess the most efficient combinations of vaccination and screening coverage for
the prevention of cervical cancer (CC) at different levels of expenditure in Nigeria.
Methods: An optimization procedure, using a linear programming approach and requiring the use of two models
(an evaluation and an optimization model), was developed. The evaluation model, a Markov model, estimated the
annual number of CC cases at steady state in a population of 100,000 women for four alternative strategies:
screening only; vaccination only; screening and vaccination; and no prevention. The results of the Markov model for
each scenario were used as inputs to the optimization model determining the optimal proportion of the
population to receive screening and/or vaccination under different scenarios. The scenarios varied by available
budget, maximum screening and vaccination coverage, and overall reachable population.
Results: In the base-case optimization model analyses, with a coverage constraint of 20% for one lifetime screening,
95% for vaccination and a budget constraint of $1 per woman per year to minimize CC incidence, the optimal mix of
prevention strategies would result in a reduction of CC incidence of 31% (3-dose vaccination available) or 46% (2-dose
vaccination available) compared with CC incidence pre-vaccination. With a 3-dose vaccination schedule, the optimal
combination of the different strategies across the population would be 20% screening alone, 39% vaccination alone and
41% with no prevention, while with a 2-dose vaccination schedule the optimal combination would be 71% vaccination
alone, and 29% with no prevention. Sensitivity analyses indicated that the results are sensitive to the constraints included
in the optimization model as well as the cervical intraepithelial neoplasia (CIN) and CC treatment cost.
Conclusions: The results of the optimization model indicate that, in Nigeria, the most efficient allocation of a limited
budget would be to invest in both vaccination and screening with a 3-dose vaccination schedule, and in vaccination
alone before implementing a screening program with a 2-dose vaccination schedule.
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The incidence of cervical cancer (CC) in the Sub-Saharan
Africa region, where Nigeria is located, is among the
highest in the world. The CC incidence per 100,000 in
Sub-Saharan Africa is 19.1 [1], whereas the world average
rate is 15.2 per 100,000. CC death rates are also high in
Sub-Saharan Africa, with rates per 100,000 of 12.8,
compared with the world average of 7.8 per 100,000. In
Sub-Saharan countries, CC is either the most common
cancer in women or the second most common cancer
(after breast cancer) in women [1].* Correspondence: nadia.x.demarteau@gsk.com
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article, unless otherwise stated.In many developed countries, where national routine
screening programs using the Papanicolaou (Pap) smear
have been implemented, the CC incidence and mortality
have been significantly reduced [2-5]. Early detection and
treatment of cervical precancerous lesions is associated
with high cure rates, whereas failure to detect precancer-
ous lesion increase the risk to CC development and hence
the risk of premature death. In many Sub-Saharan African
countries, there are currently no programs for mass CC
screening and even when such programs are set up in
family planning clinics they are perceived as cumbersome
and underutilized [6,7].
Vaccination provides an alternative or a supplementary
intervention for CC prevention. Infection with humantral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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condition for the development of CC [8-10]. Eight HPV
genotypes (HPV 16, 18, 45, 31, 33, 52, 58, and 35) account
for more than 90% of CC cases, with HPV 16 and 18 ac-
counting for about 70% of cases worldwide [11,12]. Two
HPV vaccines are currently available, an AS04-adjuvanted
HPV-16/18 vaccine and a HPV-6/11/16/18 L1 virus-like
particle vaccine that covers two non-oncogenic HPV types
(HPV 6 and 11), as well as the oncogenic types HPV 16
and 18. Both vaccines have an efficacy of approximately
98% against the HPV 16 and 18 genotypes, but have differ-
ent levels of cross-protection against other oncogenic
HPV types [13-15]. The currently approved schedule for
the available vaccines requires three doses over a 6-month
time period for optimum efficacy and is generally given
before the onset of sexual activity [16,17]. However, recent
studies have indicated that two doses of vaccine may be
sufficient and the 2-dose schedule was consequently regis-
tered in different countries worldwide including Nigeria
[18,19]. The full long term duration of protection has not
been fully determined as yet, but sustained immunogen-
icity and efficacy have been shown for up to 9.4 years for
the HPV 16/18 AS04 adjuvanted vaccine [20]. Also, a
conservative estimate from a modeling exercise estimated
that the antibody levels would remain well above levels
induced by natural infection for at least 50 years [21]. Even
though the correlate of protection is unknown, neutralizing
antibodies are considered to be the primary mechanism of
vaccine-induced protection, hence these results potentially
indicate long term protection with the vaccine.
Numerous studies have investigated the cost-effectiveness
of HPV vaccination or CC screening in many countries in
Europe, Africa, and Latin America, and most have con-
cluded that both methods of prevention are cost-effective.
Standard cost-effectiveness or budget-impact analyses
are however not the best methods to determine which
mix of prevention strategies provides the most efficient
use of limited resources. Standard cost-effectiveness
analyses do not typically take into account affordability
constraints when estimating the cost-effectiveness of
different combinations of prevention strategies, and are
also limited in their ability to examine the comparative
efficiency of many different combinations of prevention
interventions. Because neither vaccination nor screening
alone can provide 100% protection against CC, an optimal
prevention strategy might include a combination of both.
Budget-impact analyses typically estimate only affordability
and do not link budget impact to health outcomes.
An alternative approach to economic assessment is
optimization modeling applied previously in many different
areas such as transport, agriculture, industry, and banking
[22], and more recently in the health care sector [23-28].
This approach uses mathematical programming techniques
to select the combination of alternative interventions thatachieves the best clinical outcome while meeting pre-
selected constraints on the available budget and on the
feasibility of different coverage levels for the alternative
interventions.
Optimization modeling provides valuable additional
information compared with either cost-effectiveness or
budget-impact analysis, since it explicitly evaluates mul-
tiple available options to select the combination that
fulfills all the constraints introduced in the model while
obtaining the most efficient result: lowest cost for the
best outcome [22-28]. This is especially suitable for asses-
sing public health interventions, where large but limited
budgets must be allocated among different intervention
options to allow a specific health goal to be reached. Com-
pared with cost-effectiveness analysis for decision-making,
optimization modeling does not require a pre-specified
cost-effectiveness threshold, which is associated with much
debate in the literature.
The goal of this analysis was to provide information for
Nigeria, as an example of a Sub-Saharan African country
currently investigating a solution to improve CC preven-
tion, about the most efficient combinations of prevention
and screening coverage at different levels of expenditure.
Nigeria has a population of about 170 million and is also
the most populous country in Africa with a high CC
burden [29]. Moreover, women in Nigeria typically present
at an advanced CC stage; at least 80% present with stage
III disease and 10% with stage IV disease based on the
Classification of Malignant Tumours (TNM), accounting
for the observed high mortality rates [7].
We used an optimization model to identify the combi-
nations of vaccination and screening coverage that would
provide the greatest estimated reduction in the annual CC
incidence for different levels of expenditure per woman in
Nigeria. This information can be used by policy-makers in
Nigeria and other countries in Africa with similar CC inci-
dence and mortality rates when designing strategies to re-
duce the CC burden in their country.
Methods
The optimization model used in this study to identify
the optimal combination of CC prevention strategies
in Nigeria has been applied previously to the United
Kingdom (UK) and Brazil to run similar analyses [30].
This evaluation estimates the optimal mix of CC pre-
vention strategies to be implemented annually under
specific constrains at steady state to minimize CC inci-
dence. The steady state, in this evaluation, refers to a
year over which, following the implementation of the pre-
vention strategy in the entire population, all the benefits as
well as the associated costs are captured across the entire
population.
The optimization procedure requires the use of two
models. The first model embedded within the optimization
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model. It was used to generate estimates of the annual inci-
dent CC cases at steady state in a population of 100,000
women for each of four alternative strategies considered in
the evaluation: screening only; vaccination only; screening
plus vaccination; and no prevention. The number of inci-
dent CC cases was chosen as the primary outcome meas-
ure because CC prevention represents the ultimate goal of
screening or vaccination. The results of the Markov model
for each scenario were used as inputs to the optimization
model. The optimization model was then used to deter-
mine the optimal mix of interventions for maximizing the
reduction in CC incidence under different scenarios.
Those scenarios varied by available budget and by con-
straints on the maximum screening and vaccination
coverage to be reached and the overall reachable popu-
lation. Alternative scenarios were considered by varying
the screening and vaccination coverage constraints to
model different feasible intervention uptakes within a
Sub-Saharan African country such as Nigeria. The purpose
of testing different budget scenarios was to reflect the real-
ity of limited health care funding and to demonstrate the
incremental reduction in CC cases that would be possible
with additional spending. This evaluation is intended to
inform decision-makers about the health and economic
impact of different prevention strategies as well as the
optimal potential program.
Evaluation model
A previously developed Markov cohort model built in
Microsoft Excel was adapted to the Nigerian setting and
was used to estimate the clinical and cost outcomes as-
sociated with each specified prevention strategy analyzed
separately among a female population [31-33]. Screening
was assumed to be cytology-based. Eight strategies were
analyzed using the Markov model: one lifetime screening
at age 35 years; two lifetime screenings at ages 35 and
40 years; three lifetime screenings at ages 35, 40, and
45 years; vaccination of girls at age 12 years; vaccination
and one lifetime screening; vaccination and two lifetime
screenings; vaccination and three lifetime screenings;
and no prevention. The screening strategies (one, two or
three lifetime screenings) were selected to reflect the
screening programs that could be implemented in Nigeria
and other Sub-Saharan African countries.
The Markov model consisted of 12 health states, reflect-
ing the natural history of the disease and the effect of
screening and vaccination: no infection with an oncogenic
HPV virus; infection with an oncogenic HPV virus without
precancerous or cancerous lesion; cervical intraepithelial
neoplasia (CIN) grade 1; CIN grade 2 or 3; persistent
CIN grade 2 or 3; CC; diagnosed CIN grade 1 through
screening; diagnosed CIN grade 2 or 3 through screening;
diagnosed persistent CIN grade 2 or 3 through screening;CC cured; death from CC; and death from other causes
(see Figure 1).
The natural history transition rates between the different
model health states were assumed to be the same as those
used in the original Markov model [32] and were based on
published natural history studies (Table 1). The other input
values were adapted to reflect the epidemiology and costs
of CC in Nigeria whenever available, or in the continent of
Africa if country-specific data were not available [30-33]. In
particular, the incidence of HPV infection was taken from
a study of the prevalence of HPV infection in Nigerian
women, converted to incidence data based on natural
mortality in Nigeria, HPV regression and HPV progression
rate [34].
The validity of the model was assessed by comparing
the estimated age-dependent CC incidence without any
prevention strategy to the CC incidence reported in
GLOBOCAN [1]. Calibration to the reported CC inci-
dence was done by adjusting the persistent CIN2/3 to
CC transition probability.
Health care services used for treating CIN grade 1, CIN
grades 2 and 3, and CC were taken from a retrospective
chart review performed at the university college hospital at
Ibadan where patients’ charts are archived. The chart review
collected the medical resources used (outpatient health care
professional visits, outpatient diagnostic procedures, out-
patient treatment procedures, medications, and hospitali-
zations) to treat a patient with CIN1, CIN2/3 or CC. This
study received approval from the University of Ibadan/
University College Hospital Ethics Committee. For pre-
cancerous lesions, resources used over a 1-year period
from the date of diagnosis were collected; for CC, lifetime
resources were collected (from diagnosis until either death
or cure). For each condition, 10 patients with the required
information at the time of data collection (2010) were
identified (using consecutive medical records) and the
medical resources used were extracted from their hospital
medical records. The associated costs were estimated after
assigning unit costs from the hospital record to each of
the medical resources used. The costs were adjusted to
2012 values based on the Nigerian consumer price index
for the health care sector [40]. The average costs from all
patients per condition were used as input to the model
(Table 1). Health care services for screening were based
on expert opinion, and unit costs were estimated based on
the average unit costs for each procedure reported in the
hospital records from the university college hospital at
Ibadan. The cost of the vaccine program was assumed to
be $15 per dose (based on the Pan American Health
Organization (PAHO) price).
Vaccine efficacy was estimated as the weighted average
vaccine efficacy of 98% for HPV types 16 and 18 and
68.4% for the 10 most frequent non-vaccine HPV types
(HPV-31/33/35/39/45/51/52/56/58/59) related to CC,
Figure 1 Markov model flow diagram. Source: [32]. HPV: Human papillomavirus; CIN: Cervical intraepithelial neoplasia; Det: Lesion detected by
the screening.
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HPV-16/18 vaccine, with weights reflecting the relative
frequency of the different HPV types in Nigerian women
(Table 1). Matching efficacy was assumed for both the
3-dose and the 2-dose vaccination schedule.
For each prevention strategy, the Markov model esti-
mated the lifetime costs for prevention and treatment of
CIN and CC and the lifetime incident CC cases for a co-
hort of women. The lifetime outcomes from the Markov
model were divided by the total life-years lived by the
cohort and multiplied by 100,000 to provide an estimate
of 1-year values at steady state for a population of 100,000
women, assuming that the age distribution for the popula-
tion remained constant over time. These outcomes were
then used as inputs to the optimization model. Because
the estimated Markov model results were used to estimate
the steady-state, cross-sectional, 1-year values for the
whole population of interest, no discount rate was applied.
Optimization model
We used Solver (Frontline), an Excel add-in to solve the
optimization model. In the base case, we considered
only a screening frequency of once in a lifetime at age
35 years. As a result, only four prevention strategies
were included: no prevention; one lifetime screening;
vaccination alone; and vaccination plus one lifetime
screening. The optimization model was used to estimate
the proportion of the population receiving each of the CC
prevention strategies that minimized the expected CC
incidence, considering a fixed budget and pre-specified
constraints on screening coverage, vaccine coverage, andoverall reachable population. The four different CC
prevention strategies were mutually exclusive. In the
base-case analyses, the optimization model distributed
the population between the four predefined preven-







Subject to the following constraints:




Limit percentages receiving strategies to be
between 0% and 100 %: 0 ≤ xi ≤ 1 for i ¼ 1 ; :::;4













Xnprev ¼ min 1‐Coverage1½ ; 1‐Coverage2½ ð Þ
Table 1 Markov model inputs
Variable Input value Data source
Vaccination
Vaccine coverage 50% to 95% Assumption
Vaccine efficacy 16-18 98% [35,36]
Proportion of HPV 16/18 related CIN1, CIN2/3 and CC 22%, 41%, 50% [37]
Vaccine efficacy 10 other HPV oncogenic types 68.3% [36,38]
Proportion of 10 other HPV type related CIN1, CIN2/3 and CC 24%, 35% 32% [37]
Age at vaccination 12 years Assumption
Vaccine waning None Assumption
Screening
Once—age 35 years Assumption
Twice—ages 35, 40 years Assumption
Three times—ages 35, 40, 45 years Assumption
Percentage screened 20% to 40% Assumption
Cytology sensitivity CIN1 70% [39]
Cytology sensitivity CIN2/3 80% [39]
Compliance with CIN1 treatment 100% [39]
Compliance with CIN2/3 treatment 100% [39]
Efficacy of CIN treatment 95% [39]
Cost (2011 US dollars)*
Vaccine cost per dose 2365 NGN ($15) PAHO price
Cytology test 3010 NGN ($16) [40]
Colposcopy + biopsy 7225 NGN ($46) [40]
Annual CIN1 treatment (average resources used per patient: 1.7
consultations, 3.2 procedures, 1.1 medications, 0.5 hospitalizations)
40,672 NGN ($258) [40]
Annual CIN2/3 treatment (average resources used per patient: 1.8
consultations, 4.1 procedures, 2.1 medications, 0.9 hospitalizations)
68,200 NGN ($432) [40]
Lifetime CC treatment cost (average resources used per patient: 2.4
consultations, 7.1 procedures, 6.1 medications, 1.1 hospitalizations)
227,026 NGN ($1440) [40]
Transition probabilities
Age-specific mortality rate 0.01 to 1 [41]
Uninfected to HPV 0.0 to 0.14 [34]
HPV to CIN1 0.05 [42]
CIN1 to CIN 2/3 0.09 [43-45]
CIN2/3 to persistent CIN2/3 0.11 [43,44]
HPV clearance to uninfected 0.29 to 0.55 [42,44-46]**
CIN1 clearance 0.45 [43-45,47,48]
CIN 2/3 clearance 0.23 [43-45,47,48]
Persistent CIN2/3 to cancer 0.0 to 0.10 Estimated from calibration to CC
Cancer to cancer cured 0.084 Estimated from 5-year survival of 34.4% Nigeria ([1])
CIN1 = Cervical intraepithelial neoplasia, grade 1; CIN2/3 = Cervical intraepithelial neoplasia, grades 2 and 3; HPV = Human papillomavirus; NGN = Nigerian naira.
*Exchange rate used 1 NGN = $0.0063.
**Age-specific HPV clearances were used as reported in the literature.
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proportion of the population in strategy i; these fourvalues for xi are the optimization variables i (i = 1,…, 4)
that denote the four different predefined prevention
strategies: no prevention, screening once, vaccination
alone, and vaccination plus screening once.
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screening (2 strategies out of 4, 1 with screening
alone, 1 with both vaccination and screening).
■ v denotes a subset of the i strategies including
vaccination (2 strategies out of 4, 1 with vaccination
alone and 1 with both vaccination and screening).
■ xnprev represents, among the xi, the proportion of the
population receiving no preventive measure.
■ Coverage1 and Coverage2 denote the upper bounds
for coverage for screening and vaccination,
respectively; these are selected to represent either
readily achievable or ideal values.
■ CCi represents the number of CC cases at steady
state per 100,000 women receiving prevention
strategy i as estimated by the evaluation model.
■ bi is the cost for 100,000 women at steady state
receiving strategy i as estimated by the evaluation
model.
■ B is the overall CC-related (prevention and treatment)
budget across the population.
Base case analyses
The pre-vaccination budget was estimated assuming that
there is no national screening or vaccination program in
Nigeria, the associated expenditure per woman per year
being the cost of treatment for those with CC, correspond-
ing to $0.25 per woman per year across the entire female
population. In the base-case analyses, the constraint on an-
nual expenditure per woman was increased gradually from
$0.25 to $2.0, and the annual incident number of CC cases
was estimated for each level of annual expenditure when
the optimal combination of prevention strategies is imple-
mented. For the two vaccination schedules 3 and 2 doses
were considered. Three scenarios were estimated for the
full range of budget constraints: (1) maximum screening
coverage of 20% and maximum vaccination coverage of
95%; (2) maximum screening coverage of 40% and max-
imum vaccination coverage of 95%; and (3) maximum
screening coverage of 20% and maximum vaccination
coverage of 50%. These ranges were selected based on
expected or targeted ranges for screening and vaccination
coverage within the Nigerian setting. An additional con-
straint required a minimum number of people to receive
no prevention. This constraint equals the lower of one
minus the upper-bound coverage constraint for either
screening or vaccination and hence is directly linked to
the screening and vaccination coverage constraint.
Sensitivity analyses
Univariate sensitivity analyses were conducted to estimate
the effects on the incident number of CC cases for two
different budget constraints, set at $1 and $2 per woman
per year, when changing the costs associated with screen-
ing, vaccination, and treatment of CIN and CC. Ranges ofplus or minus 20% were used for the screening costs, and
ranges of plus or minus one standard deviation from the
means were used for the costs of treatment of CIN and
CC, using the data from the retrospective chart review. In
addition, the impact on CC cases of adding strategies with
more frequent screening, two lifetime screenings (at ages
35 and 40 years) or three lifetime screenings (at ages 35,
40 and 45 years), was tested. The sensitivity analysis on
treatment costs accounted for setting with higher or lower
costs than the one estimated in the retrospective cost
evaluation that may not be representative of all settings in
Nigeria. An additional scenario included the possibility of
implementing an HPV test screening instead of the Pap
test. In this scenario the cost of the screening test was set
to 50% of the Pap test costs and CIN sensitivity was in-
creased by an absolute value of 10%. Finally, the duration
of vaccine efficacy was reduced from lifetime to 25 years,




Table 2 presents the outcomes, total cost, and annual in-
cident number of CC cases for the prevention strategies
used to generate inputs for the base case and alternative
optimization model. These results indicate that screening
all women once in a lifetime ($75,418 per 100,000 women)
or providing no prevention ($26,201 per 100,000 women)
is less expensive than vaccinating all women ($191,415
and $130,603 per 100,000 women for a 3- and 2-dose vac-
cine, respectively). One lifetime screening is less effective
than vaccination at reducing incident CC cases (12.15 per
100,000 women per year with one lifetime screening, and
6.01 per 100,000 women per year with vaccination), but
more effective than no prevention (17.45 CC cases per
100,000 women per year). The most effective and expen-
sive strategy is vaccination combined with three lifetime
screenings for all women (2.74 CC cases per 100,000
women for a cost of $303,324 for a 3-dose vaccine and
$242,523 for a 2-dose vaccine).
Optimization model: base case
Figure 2A presents the optimal allocation of resources for
screening and vaccination in Nigeria at different budget
constraints (i.e., the maximum levels of expenditure per
woman per year for the prevention and treatment of CC)
with a 20% coverage limit for one lifetime screening and a
95% coverage limit for vaccination with a 3-dose vaccin-
ation schedule. The stacked columns represent the esti-
mated optimal proportion of women in the population
receiving each intervention in order to reach the maximum
CC reduction compared with pre-vaccination. Figure 2B
presents the percentage reduction in CC cases from the
pre-vaccination value of 17.45 per 100,000 women when
Table 2 Costs and clinical outcomes for women under each prevention strategy*




No prevention $26,201 ($0.26) 17.45
One lifetime screening $75,418 ($0.75) 12.15
Vaccination (3 doses) $191,415 ($1.91) 6.01
Vaccination (3 doses) and one lifetime screening $238,580 ($2.39) 4.25
Two lifetime screenings (sensitivity analysis only) $115,082 ($1.15) 9.63
Three lifetime screenings (sensitivity analysis only) $145,316 ($1.45) 7.85
Vaccination (3 doses) and two lifetime screenings (sensitivity analysis only) $275,519 ($2.76) 3.39
Vaccination (3 doses) and three lifetime screenings (sensitivity analysis only) $303,324 ($3.03) 2.74
Vaccination (2 doses) $130,603 ($1.31) 6.01
Vaccination (2 doses) and one lifetime screening $177,775 ($1.78) 4.25
Vaccination (2 doses) and two lifetime screenings (sensitivity analysis only) $214,717 ($2.15) 3.39
Vaccination (2 doses) and three lifetime screenings (sensitivity analysis only) $242,523 ($2.43) 2.74
*Inputs for the linear programming model.
**100% coverage, all women undergoing the specified strategy.
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ation is achieved at different levels of budget constraint.
Figure 2C presents the budget associated with the optimal
strategies for each set of constraints included in the
optimization model under the base-case. At maximum










































































































Budget constraint (US$) per woman per year
Figure 2 Optimal mix of prevention strategies (A), associated CC reductio
20% screening and 95% vaccination (3-dose vaccination schedule). NS = No s
lifetime screening option for screening.coverage of 95% for vaccination and 20% for one lifetime
screening, the optimal strategy would be 39% with vaccin-
ation alone, 20% with one lifetime screening, 0% with
vaccination and one lifetime screening, and 41% with no
prevention strategy. This would result in a 31% reduction



















































































Budget constraint (US$) per woman per year
n (B) and allocated budget/expenditure (C). Upper-Bound Coverage of
olution found; PV = Pre-vaccination schedule. Note: There is only a one
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vention strategies at the $1 per woman budget constraint
would be 71% with vaccination alone, 0% with one lifetime
screening, 0% with vaccination plus one lifetime screening,
and 29% with no prevention strategy. This would result in
a 46% reduction in the number of CC cases.
With a budget constraint of $2.00 per woman per year,
the maximum prevention coverage could be reached and
the optimal mix of prevention strategies to minimize CC
incidence would be (with both a 2- and a 3-dose vaccin-
ation schedule), 75% with vaccination alone, 20% with
vaccination and one lifetime screening, and 5% with no
prevention strategy. This would result in a CC reduction
of 64% with both a 3-dose and a 2-dose vaccination
schedule. The resulting expenditure would be $1.93 (3-dose
vaccination schedule) and $1.35 (2-dose vaccination
schedule) per woman per year.
Although the most effective of the four strategies in-
cluded in the base case is vaccination plus one lifetime
screening, the optimal mix of prevention strategies does
not include this combination until the budget constraint
per woman is set to $2.00 with a 3-dose vaccination
schedule and $1.50 with a 2-dose vaccination schedule.
Figures 4, 5, 6 and 7 show similar impacts of relaxing










































































































Budget constraint (US$) per woman per year
Figure 3 Optimal mix of prevention strategies (A), associated CC redu
Coverage of 20% screening and 95% vaccination (2-dose vaccination sched
Note: There is only a one lifetime screening option for screening.lifetime screening and vaccination coverage. In Figures 4
and 5, representing a scenario with a vaccination coverage
constraint of 95% and once in a lifetime screening coverage
constraint of 40%, the maximum coverage of prevention
strategies would result in an expenditure of $2.02 (3-dose
vaccination schedule) to $1.44 (2-dose vaccination sched-
ule) per woman, with an associated 66% reduction of inci-
dent CC cases. In Figures 6 and 7, which present a scenario
with a vaccination coverage constraint of 50% and a screen-
ing coverage constraint of 20%, the maximum prevention
coverage would result in an expenditure of $1.18 (3-dose
vaccination schedule) to $0.88 (2-dose vaccination sched-
ule) per woman per year, and an associated 35% reduction
in CC cases.
With a 3-dose vaccination schedule (Figures 2, 4 and
6) the optimal mix of prevention strategies includes
screening alone for the lowest budget constraint. With
a 2-dose vaccination schedule (Figures 3, 5 and 7), the
lowest budget constraints do not include screening but
include vaccination alone. Screening is only part of the
optimal mix of prevention strategies for budget con-
straints of at least $1.50 per woman per year with a
vaccination coverage constraint of 95% or at least $1.00
per woman per year with a vaccination coverage con-






















































































Budget constraint (US$) per woman per year
ction (B) and allocated budget/expenditure (C). Upper-Bound


































































Budget  constraint (US$) per woman per year
Vaccination alone Vaccination and screening























































































































Budget constraint (US$) per woman per year
Figure 4 Optimal mix of prevention strategies (A), associated CC reduction (B) and allocated budget/expenditure (C). Upper-Bound
Coverage of 40% screening and 95% vaccination (3-dose vaccination schedule). NS = No solution found; PV = Pre-vaccination schedule.
Note: There is only a one lifetime screening option for screening.
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One way sensitivity analyses were performed for a budget
constraint of $1 and $2 per woman per year. The costs of
screening and treating CIN grade 1, CIN grades 2 and
3, and CC were varied, as was the frequency of lifetime
screenings and the duration and level of protection
resulting from vaccination. An additional scenario in-
vestigated the use of a HPV test as the screening method
instead of the Pap test. The results of the sensitivity ana-
lyses, measured as the percentage of CC cases prevented
compared with the pre-vaccination incidence of CC cases
(17.45 per 100,000 women) are shown in Table 3 for a
budget constraint of $1 per woman per year and Table 4
for a budget constraint of $2 per woman per year. The re-
sults indicate that the maximum reachable CC reduction
was higher with a 2-dose than with a 3-dose vaccination
schedule under all sensitivity analyses conducted. The
optimal mix of strategies under the different sensitivity
analyses are presented in the Additional file 1: Figure S1
and Additional file 2: Figure S2. The costs of CIN and
CC treatment, as well as the vaccine characteristics, had
the largest impact on the optimal CC reduction. A low
cost led to a higher coverage of the population by a pre-
vention strategy resulting in more CC cases prevented,
while a high cost led to a lower coverage and hence a
lower CC reduction. Interestingly, the optimal strategywith a high cost for treating precancerous lesion would
imply vaccination alone or no prevention with either a
3- or a 2-dose vaccination schedule. However, the optimal
strategy with a high cost for treating cancer would com-
bine screening alone, vaccination alone and no prevention
with a 3-dose vaccination schedule, and vaccination alone,
vaccination combined with screening or no prevention
with a 2-dose vaccination schedule. The use a 2-dose
vaccine with a reduction in the vaccine efficacy also led
to a lower CC reduction under the optimal mix of strat-
egies and a combination of screening and vaccination
with however a larger vaccination coverage than with a
3-dose vaccination. The use of a HPV test for the screening
assuming a lower costs and higher sensitivity led to a higher
CC reduction while the optimal mix would combine both
screening and vaccination.
With a $2 per woman budget constraint, the maximum
vaccination and screening coverage is reached under the
optimal mix of strategies for all sensitivity analyses per-
formed, and hence the maximum CC reduction is reached
with both the 3-dose and the 2-dose vaccination schedule
scenarios and under all sensitivity analyses.
Discussion
We have developed a model that would identify the op-
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Budget constraint (US$) per woman per year
Figure 5 Optimal mix of prevention strategies (A), associated CC reduction (B) and allocated budget/expenditure (C). Upper-Bound
Coverage of 40% screening and 95% vaccination (2-dose vaccination schedule). NS = No solution found; PV = Pre-vaccination schedule.
Note: There is only a one lifetime screening option for screening.
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http://www.biomedcentral.com/1471-2407/14/365or vaccination) to minimize the number of CC cases
for different scenarios defined by constraints on budget,
maximum screening and vaccination coverage, and overall
reachable population. Under the base case, three scenarios
were considered for either a 3-dose or a 2-dose potential
vaccination schedule to capture multiple alternatives re-
garding the available budget and feasibility of implementa-
tion in Nigeria.
Main findings
The results of the Markov evaluation models indicated
that the number of CC cases expected from a 100%
coverage of each prevention strategy was lowest for
vaccination (6.01 per 100,000 women per year) com-
pared with one lifetime screening (12.15 per 100,000
women per year), two lifetime screenings (9.63 per
100,000 women per year), three lifetime screenings (7.85
per 100,000 women per year), or no prevention (17.45 per
100,000 women per year).
In the base-case optimization model analyses, with
upper-bound coverage constraints of 20% for screening
and of 95% for vaccination and a budget constraint at $1
per woman, the optimal mix of prevention strategies would
result in a 31% CC reduction compared with today’s CC
incidence with a 3-dose vaccination schedule, and in a46% CC reduction with a 2-dose vaccination schedule.
With a 3-dose vaccination schedule, the optimal combin-
ation would be 20% with screening alone, 39% with vac-
cination alone and 41% without any prevention, while
with a 2-dose vaccination schedule the optimal combin-
ation would be 0% screened, 71% vaccinated, and 29%
without any prevention. Under the lower budget con-
straints, the optimal strategy with a 3-dose vaccination
schedule would always be a combination of screening
alone, vaccination alone and no prevention, while with a
2-dose vaccination schedule the optimal combination
would only include vaccination and no prevention by
screening. Using an increment in budget constraint of
$0.25 per women per year going from $0.25 to $2.00, any
budget constraint equal to or higher than $2.00 per
woman with a 3-dose vaccination schedule, or $1.50 per
woman with a 2-dose vaccination schedule, would result
in the optimal strategy with a maximum CC reduction
using a strategy consisting of 75% with vaccination alone,
20% with vaccination and screening and 5% without pre-
vention. The associated CC reduction would be 64%.
These strategies would be specifically associated with a
budget of $1.93 per woman with a 3-dose vaccination
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Budget constraint (US$) per woman per year
Figure 6 Optimal mix of prevention strategies (A) associated CC reduction (B) and allocated budget/expenditure (C). Upper-Bound
Coverage of 20% screening and 50% vaccination (3-dose vaccination schedule). NS = No solution found; PV = Pre-vaccination schedule.
Note: There is only a one lifetime screening option for screening.
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http://www.biomedcentral.com/1471-2407/14/365The results were similar for different screening and
vaccination coverages, except that in the case of an
upper-bound vaccination coverage of 50%, the percentage
reduction in CC cases compared with the pre-vaccination
situation had a maximum value of 35% at an expenditure
of $1.18 per woman with a 3-dose vaccination schedule
and $0.88 per woman with a 2-dose vaccination schedule.
Sensitivity analyses indicated that the results were sensi-
tive to the CIN and CC treatment cost. Higher treatment
costs resulted in lower achievable coverage with vaccin-
ation and screening within the $1 budget constraint,
and hence a lower reduction in the number of CC cases.
With a 2-dose vaccination schedule, all sensitivity ana-
lyses tended to first maximize the vaccination coverage.
With a 3-dose vaccination schedule, most sensitivity
analyses (except a high CIN treatment cost) tended to
maximize both vaccination and screening and in all cases
resulted in a lower reduction in CC than the reduction ob-
tained with a 2-dose vaccination schedule.
The results from the optimization model indicate that
when introducing a prevention program for CC, in a
country like Nigeria where none is currently in place,
with a 2-dose vaccination schedule it would be optimal to
invest in vaccination alone to the extent feasible, followed
by vaccination plus one lifetime screening. With a 3-dose
vaccination schedule, a combination of both vaccinationand screening would be optimal. This result depends
therefore on the relative costs of vaccination and screening
as well as the relative efficacy between the two interven-
tions. The optimization would favor a strategy with a low
costs and a high efficacy (sensitivity for the screening).
A similar model was recently used to estimate the
optimal mix of CC screening and HPV vaccination in
the UK and Brazil [30]. These two countries already
had a screening program in place, with coverage levels
of 65% in the UK and 50% in Brazil, each with a screen-
ing frequency of 3 years applied to all screened women.
The optimization model indicated that keeping the
existing screening program while extending the screen-
ing interval to 6 years and adding vaccination with 80%
coverage would result in a reduction in CC cases of
41% in the UK and 54% in Brazil, with no change in
expenditure per woman compared with the pre-vaccination
situation. This is very different from the situation ob-
served in Nigeria, where no nationwide screening pro-
grams are currently in place and one lifetime screening
is standard for the few women who are screened. As a
result, reducing CC in Sub-Saharan Africa will require
that additional resources be spent per woman on either
screening or HPV vaccination programs.
The current evaluation estimated that an optimal allo-
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Budget constraint (US$) per woman per year
Figure 7 Optimal mix of prevention strategies (A) associated CC reduction (B) and allocated budget/expenditure (C). Upper-Bound
Coverage of 20% screening and 50% vaccination (2-dose vaccination schedule). NS = No solution found; PV = Pre-vaccination schedule.
Note: There is only a one lifetime screening option for screening.
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http://www.biomedcentral.com/1471-2407/14/365year could lead to an important reduction in CC burden
by 31% to 46%, depending on the scenario chosen. In
Nigeria, three tiers of Government (Federal, State and
Local) have responsibility for health and decide about
budget allocation. The current evaluation suggests that a
combination of 2-dose vaccination with or without one
lifetime screening is expected to lead to an important
reduction in CC.
Nationwide deployment of HPV vaccines to reduce
the CC burden in Africa is more realistic than imple-
menting a screening program, given the current fail-
ure of the national screening program due to logistic
and funding challenges. Most African countries have
efficient and very well accepted national childhood
immunization programs, as in Nigeria. HPV vaccin-
ation could be integrated into these programs, provided
some operational challenges linked to the adaptation
of the program to a different target population (adoles-
cent for the HPV vaccination) are addressed. The cost
of implementation would also be drastically reduced
compared to that expected from the implementation of
a screening program. However, in each country the age
at which the vaccination is implemented should be
adapted based on their national average age of girls’
sexual debut.Limitations of the optimization analysis
The optimization model used for this analysis has its
limitations. First, the model outcome is obtained when an
optimal mix of different prevention strategies is applied in
the population and a steady-state incidence of CC is
achieved across the population. Many years will elapse
before reaching that state. The results therefore represent
an optimal “ideal” situation that provides a direction to be
followed but not a result that will occur immediately, and
nor does it address specific implementation issues. Vaccin-
ation will affect the girls who will become the women of
the future. Today’s women would not benefit from vaccin-
ation, but could directly benefit from a single lifetime
screening. The vaccinated girls would not need any
screening in the years post vaccination. This cost saving
could be used to implement a screening program bene-
fiting older women. This would accelerate the overall
CC reduction. No discounting was applied in this ana-
lysis, as the model presents a steady-state evaluation
over a 1-year period. Given the time lag needed to reach
steady state, discounting could be considered, but the
means of implementation and especially the value of in-
cluding a discount rate in such an optimization exercise is
debatable. A discounting applied to the input of the model
down to a today value would not impact the optimization
Table 3 Annual CC cases and change from the pre-vaccination situation under the optimal budget allocation







Base case (3 doses)
Base case—mean treatment costs and one lifetime screening 12.0 (−31%) 11.6 (−34%) 12.1 (−31%)
Prevention cost minus 20% and CIN treatment costs minus 1 SD 11.6 (−34%) 10.8 (−38%) 12.3 (−29%)
Prevention costs plus 20% and CIN treatment costs plus 1 SD 12.3 (−29%) 12.3 (−29%) 12.1 (−31%)
CC treatment costs minus 1 SD 10.7 (−38%) 10.4 (−40%) 11.7 (−33%)
CC treatment costs plus 1 SD 13.5 (−23%) 13.1 (−25%) 13.5 (−23%)
Allow scenarios with two lifetime screenings 12.0 (−31%) 11.6 (−34%) 12.1 (−30%)
Allow scenarios with two or three lifetime screenings 12.0 (−31%) 11.6 (−34%) 12.1 (−31%)
Screening using HPV test 11.6 (−34%) 10.8 (−38%) 12.0 (−31%)
Vaccine (3 doses) duration of protection = 25 years, vaccine efficacy reduced by 20% 12.8 (−27%) 12.3 (−30%) 13.1 (−25%)
Alternative scenario (2 doses)*
Base case mean treatment costs and one lifetime screening 9.4 (−46%) 9.4 (−46%) 11.0 (−37%)
Prevention cost minus 20% and CIN treatment costs minus 1 SD 8.8 (−50%) 8.4 (−52%) 11.0 (−37%)
Prevention costs plus 20% and CIN treatment costs plus 1 SD 9.4 (−46%) 9.4 (−46%) 11.1 (−36%)
CC treatment costs minus 1 SD 7.9 (−55%) 7.9 (−55%) 11.0 (−37%)
CC treatment costs plus 1 SD 11.4 (−35%) 11.4 (−35%) 11.6 (−33%)
Allow scenarios with two lifetime screenings 9.4 (−46%) 9.4 (−46%) 11.0 (−37%)
Allow scenarios with two or three lifetime screenings 9.4 (−46%) 9.4 (−46%) 11.0 (−37%)
Screening using HPV test 8.8 (−49%) 8.5 (−51%) 11.3 (−35%)
Vaccine (2 doses) duration of protection = 25 years, vaccine efficacy reduced by 20% 10.8 (−38%) 10.6 (−39%) 12.3 (−29%)
Sensitivity analyses: budget constraint $1 (~4 times pre-vaccination budget) per woman.
V-S(int)-V&S-None.
CIN = Cervical intraepithelial neoplasia; CC = Cervical cancer; SD = Standard deviation.
*assume, in the base case, the same efficacy for a three or a two dose vaccine.
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http://www.biomedcentral.com/1471-2407/14/365results while ways to implement the optimization on a
population overtime still need to be investigated.
Second, a static Markov model was used to evaluate
the cost and outcomes of each potential strategy at
steady state across a population over a 1-year period.
As the optimization model takes results from the evalu-
ation model, the robustness of the optimization results
therefore also depends upon the validity of the evaluation
model. The Markov model used for this analysis did not
account for dynamic effects of vaccination on infection,
such as herd protection. It also assumed stability in the
population demographic structure over time. However,
using a dynamic model as the evaluation model instead
of the static model would be more difficult to adapt to
countries with limited data. It would also lead to non-
linearity between coverage and the outcomes, and thus
would require the use of a nonlinear programming
optimization model.
Third, the models presented here are deterministic:
costs and effects in all combinations are known. It would
be possible to characterize the allocation problem under
conditions of uncertainty by reformulating the model asa stochastic analysis. However, existing approaches for
such stochastic analyses are limited [49]. This is an area
for future research, although the principal outcome of
evaluating uncertainty is to indicate the need and the
potential value of searching for more detailed and specific
information [49].
Fourth, the results depend on the strategies initially
investigated using the evaluation model. Therefore, in-
cluding a vaccine with a different profile or a screening
program with different characteristics (e.g., HPV testing
instead of cytology-based screening) may lead to other
optimal scenarios, as presented in the sensitivity analysis
conducted in the current evaluation. Furthermore, the
analysis does not take into account the possibility that the
introduction of vaccination may affect the sensitivity of
the screening test [50,51]. It also does not account for
the cost associated with the implementation of a screen-
ing or vaccination program in Nigeria. Finally, our model
assumes that the interventions evaluated are completely
divisible in terms of intervals between screening tests and
coverage. It ignores possible fixed set-up and implementa-
tion costs associated with interventions, which could
Table 4 Annual CC cases and change from the pre-vaccination situation under the optimal budget allocation







Base case (3 doses)
Base case—mean treatment costs and one lifetime screening 6.2 (−64%) 6.0 (−66%) 11.4 (−35%)
Prevention cost plus 20% and CIN treatment costs plus 1 SD 6.2 (−64%) 5.9 (−66%) 11.4 (−35%)
Prevention costs minus 20% and CIN treatment costs minus 1 SD 6.2 (−64%) 6.1 (−65%) 11.4 (−35%)
CC treatment costs plus 1 SD 6.2 (−64%) 5.9 (−66%) 11.4 (−35%)
CC treatment costs minus 1 SD 6.2 (−64%) 6.3 (−64%) 11.4 (−35%)
Allow scenarios with two lifetime screenings 6.1 (−65%) 6.0 (−66%) 11.2 (−36%)
Allow scenarios with two or three lifetime screenings 5.9 (−66%) 6.0 (−66%) 11.1 (−37%)
Screening using HPV test 6.2 (−65%) 5.8 (−67%) 11.3 (−35%)
Vaccine duration of protection = 25 years, vaccine efficacy reduced by 20% 7.3 (−58%) 7.1 (−59%) 12.0 (−31%)
Alternative scenario (2 doses)*
Base case—mean treatment costs and one lifetime screening 6.2 (−64%) 5.9 (−66%) 11.4 (−35%)
Prevention cost plus 20% and CIN treatment costs plus 1 SD 6.2 (−64%) 5.9 (−66%) 11.4 (−35%)
Prevention costs minus 20% and CIN treatment costs minus 1 SD 6.2 (−64%) 5.9 (−66%) 11.4 (−35%)
CC treatment costs plus 1 SD 6.2 (−64%) 5.9 (−66%) 11.4 (−35%)
CC treatment costs minus 1 SD 6.2 (−64%) 5.9 (−66%) 11.4 (−35%)
Allow scenarios with two lifetime screenings 6.1 (−65%) 5.5 (−68%) 11.2 (−36%)
Allow scenarios with two or three lifetime screenings 5.9 (−66%) 5.3 (−70%) 11.1 (−37%)
Screening using HPV test 6.2 (−65%) 5.8 (−67%) 11.3 (−35%)
Vaccine duration of protection = 25 years, vaccine efficacy reduced by 20% 8.1 (−54%) 7.7 (−56%) 12.3 (−29%)
Sensitivity analyses: budget constraint $2 (~8 times pre-vaccination budget) per woman.
CIN = Cervical intraepithelial neoplasia; CC = Cervical cancer; SD = Standard deviation.
*assume, in the base case, the same efficacy for a three or a two dose vaccine.
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http://www.biomedcentral.com/1471-2407/14/365constrain their divisibility. The fixed costs could be large
for screening coverage, such as setting up the necessary
infrastructure to collect and analyze samples, or imple-
menting health education programs to increase awareness
and overcome psychological and cultural barriers to up-
take. Conversely, they may be relatively low for vaccine
implementation in situations where other vaccination pro-
grams in the relevant age group are already established. In
addition, the incremental implementation cost by coverage
is unlikely to be linear. Disregarding such indivisible or
nonlinear costs could be important in practice. Given the
importance of the relative costs of vaccination and screen-
ing to the selection of the optimal program, the inclusion
of these costs could have a large impact on the results.
Conclusions
The optimization model presented here provides infor-
mation needed to inform health policy decisions on the
optimal allocation of limited resources to prevent CC
most effectively. The results indicate that increased spend-
ing will be needed in Nigeria and in other countries in
Sub-Saharan Africa that currently lack a CC prevention
program, in order to achieve adequate prevention of CCcases. With a 3-dose vaccination schedule, the most effi-
cient allocation of a limited budget would be to invest in
both vaccination and screening, while with a 2-dose vac-
cination schedule investment should first be directed to
vaccination before implementing a screening program.Note
All costs are in USD ($ in the text).
Additional files
Additional file 1: Optimal mix of strategies under the optimal
budget allocation. (a) vaccination overage 95%, screening coverage
20%; (b) vaccination coverage 95% screening coverage 40%; (c)
vaccination coverage 50% screening coverage 20%. Sensitivity Analyses:
Budget Constraint $1 (~4 times Pre-vaccination Budget) per Woman.
CC = Cervical cancer; 2LT = Two lifetime screenings; 3LT = Three lifetime
screenings; HPV = Human papillomavirus; VE = Vaccine efficacy.
Additional file 2: Optimal mix of strategies under the optimal
budget allocation. (a) vaccination overage 95%, screening coverage
20%; (b) vaccination coverage 95% screening coverage 40%; (c)
vaccination coverage 50% screening coverage 20%. Sensitivity Analyses:
Budget Constraint $2 (~8 times Pre-vaccination Budget) per Woman.
CC = Cervical cancer; 2LT = Two lifetime screenings; 3LT = Three lifetime
screenings; HPV = Human papillomavirus; VE = Vaccine efficacy.
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